Title |
Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity
|
---|---|
Published in |
Molecular Cancer Therapeutics, January 2021
|
DOI | 10.1158/1535-7163.mct-20-0405 |
Pubmed ID | |
Authors |
Sang-In Kim, Anthony K. Park, Shyambabu Chaurasiya, Seonah Kang, Jianming Lu, Annie Yang, Venkatesh Sivanandam, Zhifang Zhang, Yanghee Woo, Saul J. Priceman, Yuman Fong, Susanne G. Warner |
X Demographics
The data shown below were collected from the profiles of 31 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 16 | 52% |
Australia | 2 | 6% |
Canada | 1 | 3% |
Denmark | 1 | 3% |
Unknown | 11 | 35% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 15 | 48% |
Scientists | 12 | 39% |
Science communicators (journalists, bloggers, editors) | 2 | 6% |
Practitioners (doctors, other healthcare professionals) | 2 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 23 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 5 | 22% |
Student > Bachelor | 3 | 13% |
Student > Master | 3 | 13% |
Student > Doctoral Student | 2 | 9% |
Student > Ph. D. Student | 2 | 9% |
Other | 0 | 0% |
Unknown | 8 | 35% |
Readers by discipline | Count | As % |
---|---|---|
Immunology and Microbiology | 5 | 22% |
Medicine and Dentistry | 3 | 13% |
Biochemistry, Genetics and Molecular Biology | 3 | 13% |
Agricultural and Biological Sciences | 3 | 13% |
Arts and Humanities | 1 | 4% |
Other | 1 | 4% |
Unknown | 7 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 264. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 June 2022.
All research outputs
#139,642
of 26,017,215 outputs
Outputs from Molecular Cancer Therapeutics
#19
of 4,105 outputs
Outputs of similar age
#4,079
of 530,381 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#1
of 58 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,105 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 530,381 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 58 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.